Our recent results also reveal that a distinct SL profile, i.e., a tendency for increased very long-chain ceramide species, was observed in the plasma of patients with melanoma who achieve a response to a BRAF-targeted therapy as compared with patients with progressive disease [64]. This evidence concerns the gene BRAF and melanoma.